D-0235-2022 Class III Terminated
FDA drug recall D-0235-2022 was initiated by Teva Pharmaceuticals USA on Oct 28, 2021 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Feb 27, 2023). Affected quantity: 64,978 patches.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 24, 2021
- Initiation Date
- Oct 28, 2021
- Termination Date
- Feb 27, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 64,978 patches
Product description
Clonidine Transdermal System, USP 0.1 mg/day, 4 patches per carton, Rx only, Manufactured by: Actavis Laboratories, UT Inc., Salt Lake City, UT, Distributed by: Actavis Pharma, Inc., Parsippany, NJ NDC 0591-3508-04
Reason for recall
Failed Impurities/Degradation Specifications
Distribution pattern
Nationwide and Puerto Rico
Code information
Lot# 1369117B, exp. date 11/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0235-2022
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026